{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["4(4)"],"submitter":["Zhu E"],"pubmed_abstract":["<h4>Background</h4>IL-13 plays a key role in the induction and perpetuation of type 2 immune responses associated with the development of atopic dermatitis and other chronic inflammatory diseases. mAbs targeting IL-13 have demonstrated efficacy in IL-13-driven diseases; however, current therapeutics require dosing every 2 to 4 weeks, resulting in significant injection burden for patients. APG777 is a humanized, IgG1 IL-13-targeting mAb that has been engineered to have an optimized pharmacokinetic profile, allowing for less frequent dosing.<h4>Objective</h4>We sought to investigate the <i>in vitro</i> potency and <i>in vivo</i> pharmacokinetics of APG777.<h4>Methods</h4>The affinity of APG777 was characterized using surface plasmon resonance; the half-maximal inhibitory concentration (IC<su"],"journal":["The journal of allergy and clinical immunology. Global"],"pagination":["100545"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12419008"],"repository":["biostudies-literature"],"pubmed_title":["&lt;i&gt;In vitro&lt;/i&gt; potency and pharmacokinetics of APG777, a novel anti-IL-13 mAb."],"pmcid":["PMC12419008"],"pubmed_authors":["Prentice H","Dabora R","Oh J","Shaheen H","Dambkowski CL","Zhu E","Gandhi NA","Wickman G","Dillinger L"],"additional_accession":[]},"is_claimable":false,"name":"&lt;i&gt;In vitro&lt;/i&gt; potency and pharmacokinetics of APG777, a novel anti-IL-13 mAb.","description":"<h4>Background</h4>IL-13 plays a key role in the induction and perpetuation of type 2 immune responses associated with the development of atopic dermatitis and other chronic inflammatory diseases. mAbs targeting IL-13 have demonstrated efficacy in IL-13-driven diseases; however, current therapeutics require dosing every 2 to 4 weeks, resulting in significant injection burden for patients. APG777 is a humanized, IgG1 IL-13-targeting mAb that has been engineered to have an optimized pharmacokinetic profile, allowing for less frequent dosing.<h4>Objective</h4>We sought to investigate the <i>in vitro</i> potency and <i>in vivo</i> pharmacokinetics of APG777.<h4>Methods</h4>The affinity of APG777 was characterized using surface plasmon resonance; the half-maximal inhibitory concentration (IC<su","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-05-26T11:08:24.596Z","creation":"2026-05-24T03:07:06.316Z"},"accession":"S-EPMC12419008","cross_references":{"pubmed":["40933957"],"doi":["10.1016/j.jacig.2025.100545"]}}